SkyCell, a Swiss startup that is transforming the pharmaceutical supply chain, has received $116 million in Series D funding. This funding is divided between $59 million from Tybourne Capital Management and CCI, and $57 million in equity investment from Catalyst and M&G Investments, which is a purpose-led private asset strategy. The company said that this investment makes SkyCell one of the leading deep-tech companies in Europe at a time when the pharmaceutical industry is experiencing rapid growth due to high-value goods that require careful transportation.